The outcome is reminiscent of the SELECT, a phase II trial of adjuvant erlotinib in EGFR mutant NSCLC patients (N = 100), wherein the disease recurred in 4 of 40 patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.